(The Hill) — A new poll from the health policy nonprofit KFF found that one in eight adults say they’ve taken a GLP-1 agonist ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The plaintiffs' attorneys claim that GLP-1 drugs ... of health and drug trends. A recent poll by the Kaiser Family Foundation found the number of adults who have taken such drugs may be ...

Lexaria's DehydraTECH-processed Rybelsus ® capsules demonstrated superior tolerability in delivering the GLP-1 drug semaglutide ... Blood samples were taken multiple times during the first ...

Novo Nordisk’s stock value surged by over 8% following the drug’s presentation at an investor meeting on March 7, 2024.. The surging interest in a new class of medications known as GLP-1 ...

The maker of a weight loss drug has asked regulators to allow them to expand the use of the medication down to the age of six. It comes as Liraglutide, a drug approved to treat obesity in adults and ...

Thus, semaglutide’s appetite-suppressing effect makes it a useful drug for weight loss and management when used in conjunction with diet and exercise. Obesity in adults ... US are currently on a ...

Most adults and children 12 and older have access to highly effective new medicines called GLP-1 receptor agonists ... was approved by the US Food and Drug Administration in 2014 to help adults ...